PFS Boost With Atezolizumab in Advanced Squamous NSCLC

Article

The addition of atezolizumab to chemotherapy was associated with superior PFS but did not improve preliminary OS.

Adding atezolizumab immunotherapy to chemotherapy is associated with a reduced risk of tumor progression and death among patients with advanced squamous non–small-cell lung cancer (NSCLC), according to initial findings from the randomized phase III IMpower 131 study (ClinicalTrials.gov identifier: NCT02367794; abstract LBA9000). The findings were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1–5 in Chicago.

The combination was associated with twice the investigator-assessed 12-month progression-free survival (PFS) rate compared with carboplatin and nab-paclitaxel–based chemotherapy alone (24.7% vs 12.0%; hazard ratio [HR], 0.71; 95% CI, 0.60–0.85; P = .0001), reported lead study author Robert M. Jotte, MD, PhD, of Rocky Mountain Cancer Centers, Denver, Colorado.

“We used to think that chemotherapy just knocked down the patient’s immune system and that it would be irrational to combine it with immunotherapy, but growing research, including this study, shows that chemotherapy can help trigger the immune response to the tumor, helping the immunotherapy treatment to work better,” Jotte said.

Atezolizumab targets programmed death ligand 1 (PD-L1), but patient benefits did not depend on tumor PD-L1 expression, Jotte reported.

Patients received 4 or 6 cycles of chemotherapy with (n = 343) or without atezolizumab (n = 340) until progression.

Nearly all patients experienced treatment-related adverse events (94.6% of those receiving atezolizumab with chemotherapy and 90.7% of those receiving only carboplatin and nab-paclitaxel). Serious toxicities were reported for 20% and 10.5% of patients in the atezolizumab and control groups, respectively.

“The safety profile was consistent with the known risks of the individual treatment components,” Jotte reported. “No new safety signals were identified.”

Confirmed objective response rates were higher and duration of response was longer with atezolizumab plus chemotherapy than with chemotherapy alone, regardless of PD-L1 expression.

Interim overall survival (OS) in the intent-to-treat population was nearly identical between the study arms (14 months vs. 13.9 months in the control group).

“Overall survival continues to be followed, with the next interim OS analysis anticipated late in 2018,” Jotte said.

Jotte disclosed financial relationships with Bristol-Myers Squibb.

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content